Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of combination pembrolizumab and olaparib in patients with advanced cholangiocarcinoma: Interim results.
Authors
Chao Yin
Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
Chao Yin , Samantha Ann Armstrong , Seema Agarwal , Hongkun Wang , Marcus Smith Noel , Benjamin Adam Weinberg , John Marshall , Aiwu Ruth He
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04306367
DOI
10.1200/JCO.2022.40.4_suppl.452
Abstract #
452
Poster Bd #
C9
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.
First Author: Aiwu Ruth He
Poster
2024 ASCO Annual Meeting
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.
First Author: Joachim Aerts
Poster
2019 Gastrointestinal Cancers Symposium
Halo 110-101: Early safety results of pegvorhyaluronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) ± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC).
First Author: Do-Youn Oh